Edwards Lifesciences Corporation $EW Shares Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. boosted its stake in Edwards Lifesciences Corporation (NYSE:EW) by 39.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,286,298 shares of the medical research company’s stock after purchasing an additional 648,870 shares during the quarter. Assenagon Asset Management S.A. owned about 0.39% of Edwards Lifesciences worth $194,907,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. JPL Wealth Management LLC purchased a new stake in Edwards Lifesciences during the third quarter valued at about $25,000. True Wealth Design LLC raised its holdings in shares of Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after purchasing an additional 259 shares during the period. Hantz Financial Services Inc. lifted its stake in shares of Edwards Lifesciences by 76.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares in the last quarter. Rakuten Securities Inc. lifted its stake in shares of Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 302 shares in the last quarter. Finally, Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter worth about $30,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Wells Fargo & Company increased their target price on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Piper Sandler reiterated an “overweight” rating and set a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Stifel Nicolaus set a $110.00 price objective on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Tuesday, January 20th. JPMorgan Chase & Co. raised shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and raised their target price for the company from $90.00 to $100.00 in a research note on Thursday, December 18th. Finally, Canaccord Genuity Group set a $87.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Wednesday, December 17th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $96.14.

Edwards Lifesciences Stock Down 0.7%

NYSE EW opened at $81.95 on Tuesday. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The business has a 50 day moving average price of $82.21 and a two-hundred day moving average price of $81.65. The stock has a market cap of $47.59 billion, a PE ratio of 44.78, a P/E/G ratio of 2.15 and a beta of 0.93.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The firm had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,371,239.08. The trade was a 24.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $85.38, for a total value of $87,002.22. Following the sale, the vice president owned 33,934 shares of the company’s stock, valued at approximately $2,897,284.92. This trade represents a 2.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 61,718 shares of company stock valued at $5,236,281 in the last quarter. Company insiders own 0.34% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.